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Abstract
Catechol-O-methyltransferase (COMT) metabolizes catecholaminergic neurotransmitters. Numerous studies have linked
COMT to pivotal brain functions such as mood, cognition, response to stress, and pain. Both nociception and risk of clinical
pain have been associated with COMT genetic variants, and this association was shown to be mediated through adrenergic
pathways. Here, we show that association studies between COMT polymorphic markers and pain phenotypes in 2
independent cohorts identified a functional marker, rs165774, situated in the 39 untranslated region of a newfound splice
variant, (a)-COMT. Sequence comparisons showed that the (a)-COMT transcript is highly conserved in primates, and deep
sequencing data demonstrated that (a)-COMT is expressed across several human tissues, including the brain. In silico
analyses showed that the (a)-COMT enzyme features a distinct C-terminus structure, capable of stabilizing substrates in its
active site. In vitro experiments demonstrated not only that (a)-COMT is catalytically active but also that it displays unique
substrate specificity, exhibiting enzymatic activity with dopamine but not epinephrine. They also established that the pain-
protective A allele of rs165774 coincides with lower COMT activity, suggesting contribution to decreased pain sensitivity
through increased dopaminergic rather than decreased adrenergic tone, characteristic of reference isoforms. Our results
provide evidence for an essential role of the (a)-COMT isoform in nociceptive signaling and suggest that genetic variations in
(a)-COMT isoforms may contribute to individual variability in pain phenotypes.
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1. Introduction
Catecholamine-O-methyltransferase (COMT) is an enzyme
widely expressed in the human body. In its soluble (S-COMT) or
membrane-bound (MB-COMT) isoform, it methylates and
consequently deactivates catechol-containing substrates,
such as the catecholamines epinephrine, norepinephrine,
and dopamine. Catechol-O-methyltransferase is involved in
a variety of biological functions, including—but not limited
to—mood, cognition, response to stress, and pain perception.
In humans, increased sensitivity to noxious stimuli and risk of
developing a chronic pain condition have been associated with
COMT genetic variants coding for decreased COMT
activity.7,33 This association has been shown to be mediated
by the activation of b2- and b3-adrenergic receptors,34 and
treatment of patients with chronic facial pain (temporoman-
dibular disorder, TMD) using a nonselective b-blocker has
been shown to be effective in a COMT haplotype-dependent
manner.50
Here, using human genetic association studies, we identi-
fied a functional single nucleotide polymorphism (SNP) within
the COMT gene locus—rs165774—that is associated with the
risk of TMD and individual variability in sensitivity to painful
stimuli. This finding led us to the identification of a novel
functional alternatively spliced COMT isoform, now with
a different C-terminus. We further show that this isoform is
expressed in a variety of human tissues and that it encodes
a functional enzyme isoform. This enzyme displays dramati-
cally different affinities for catecholamine substrates than the
reference S- and MB-COMT isoforms. In contrast to the
reference isoforms, decrease in the activity of the newly
discovered isoform is associated with reduced susceptibility to
a common musculoskeletal pain condition (TMD) and lower
sensitivity to certain painful stimuli.
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2. Methods
2.1. Description and analyses of TMD case–control and
OPPERA cohorts
For the association analysis, phenotypic data were obtained from
2 independent cohorts and fully described elsewhere.5,14
Approval from the institutional review board of The University of
North Carolina at Chapel Hill (NC) was obtained for the TMD
case–control cohort and from the institutional review boards of
each of the 4 study sites and the data-coordinating center
participating in the OPPERA study (Orofacial Pain: Prospective
Evaluation and Risk Assessment) cohort, namely, The University
of Maryland at Baltimore (MD), The University of Buffalo (NY), The
University of North Carolina at Chapel Hill (NC), The University of
Florida at Gainesville (FL), and Battelle Memorial Institute (NC). All
subjects participating in either one of the cohort provided signed
informed consent.
First, a TMD case–control cohort was recruited at the
University of North Carolina at Chapel Hill, as described
elsewhere.4 This cohort (Caucasian females, aged 18-55 years)
consisted of 198 healthy controls and 200 TMD cases, identified
using the Research Diagnostic Criteria for TMD (RDC/TMD).11
Quantitative sensory testing (QST) was performed on all subjects
and 2 experimental pain modalities were tested, pressure pain
and heat pain that produced 5 QST variables: pressure pain, heat
pain, heat pain first pulse and heat pain sum (measures of heat
pain sensitivity to a suprathreshold heat stimulus), and the
temporal summation of heat pain (heat pain rate of rise).5
Results were replicated in an independent cohort, OPPERA.29
We used a subset of the OPPERA cohort that included only
Caucasian females and consisted of 106 TMD cases and 859
controls. In this cohort, QST was conducted in the same sensory
domains as the discovery cohort (pressure and heat pain) and in 1
additional sensory domain: mechanical cutaneous pain. For the
sensory domain of heat pain, 1 additional variable was produced:
heat pain after sensation.14 For the sensory domain of mechanical
cutaneous pain, 4 new variables were analyzed: mechanical pain
threshold, mechanical pain single stimulus, mechanical pain
windup, and mechanical pain after sensation.14 Thus, 5 additional
pain measures were included in the replication analysis.
Genotypic data for both cohorts were obtained using the
Algynomics (Chapel Hill, NC) Pain Research Panel: a chip-based
platform that consists of 3295SNPs representing 358genes known
to be involved in systems relevant to pain perception. Within each
gene, SNPs were prioritized for inclusion based on known
functionality (ie, they result in nonsynonymous amino acid changes,
expression level differences, or disrupted alternative splicing). Other
SNPs were selected as representative markers of regions with high
linkage disequilibrium (LD), containing many correlated SNPs that
are inherited in blocks, to tag untyped SNPs.46
For the TMD case–control cohort, all 9 SNPs situated within the
COMT gene locus (rs2020917, rs737865, rs1544325, rs6269,
rs4633, rs165774, rs174697, rs9332381, and rs165599) were
tested for their association with TMD. All SNPs were in Hardy–
Weinberg equilibrium. Association was tested using logistic re-
gression with age as a covariate term and assuming additive effects
using PLINK v.1.07 (Broad Institute, Cambridge, MA).37 We used
spectral decomposition27 to estimate the number of effectively
independent SNPs tested after accounting for the LD between
neighboring SNPs, to generate a P value threshold to retain an
experiment-wide alpha value of P 5 0.008512. Of all densely
situated SNPs tested within the COMT gene locus, only SNP
rs165774 was significantly associated with TMD. Because COMT-
dependent pain and risk of TMD have been previously shown to be
determined by 3 major COMT haplotypes—low, average (APS),
and high pain sensitivity (HPS) haplotypes, constructed from SNPs
rs6269, rs4633, rs4818, and rs46808,46—we looked for the
relationship between these haplotypes and SNP rs165774.
Because SNPs rs6269 and rs4818, and SNPs rs4633 and
rs4680, are in complete LD in Caucasian population, and SNPs
rs4818 and rs4680 are tagged by SNPs rs6269 and rs4633,
respectively, in thePainResearchPanel, we usedSNPs rs6269and
rs4633 for haplotypes reconstruction using Haploview.3 Associa-
tion between constructed haplotypes and risk of TMD was then
tested. For that, logistic regression including age as a covariate term
and assuming additive effects was performed on PLINK. Associ-
ation analysis between constructed haplotypes and risk of TMD
revealed to be completely driven byminorA allele of SNP rs165774.
Given the power of the association betweenSNP rs165774 and risk
of TMD, which drives the association between APS haplotype and
this pain phenotype, we focused our study on the effects of this
SNP. Then, we looked further for the association between SNP
rs165774 and all QST using linear regression, using age and TMD
case status as covariate terms.
In the OPPERA cohort, haplotypes were also reconstructed
using Haploview,3 and association between SNP rs165774 and
risk of TMD and a battery of QST tests were performed using
logistic or linear regression, respectively, using either age and site
of data collection or age, site of data collection, and TMD case
status as covariate terms, also, respectively.
Common phenotypes between TMD case–control and
OPPERA cohorts were combined by meta-analysis, performed
using the R package “metaphor.”55
2.2. Gene structure and mRNA expression of the new
catechol-O-methyltransferase isoform
Multiple alignments ofmammalian orthologous regions for human
alternative COMT isoform were created using the Muscle
sequence alignment software.12 Alternative COMT regions were
mapped to mammalian genomes using BLAST1 or LiftOver.20 On
the basis of the reciprocal BLAST hits, we identified 15
orthologous regions for alternative COMT variants in different
mammalian genomes. Phylogenetic analysis was conducted
using MEGA5 and RAxML software.47,49 RNA–RNA intermolec-
ular interactions and miRNA targets were predicted by Thermo-
Composition software and Afold program.31,35,42
We used the mRNA-Seq data from Gene Expression Omnibus
set number GSE30352.6 Single-ended reads (76 nucleotides)
were split into 2, whereas fused pair–ended reads (202
nucleotides) were split into 4 and mapped in a single-ended
fashion. This simplifies the mapping procedure as the reads are
very long and the mismatch leeway is set to a maximum of 2. The
data were mapped with Bowtie version 1.0.0,25 using all default
options and including the option to discard all reads mapping to
more than 1 locus (2m 1). Versions for genomes are hg19
(UCSC) for Homo sapiens, panTro4 (UCSC) for Pan troglodytes,
and gorGor75 (Ensembl) for Gorilla gorilla. Genomes and Bowtie
index files were all downloaded from iGenomes (http://support.
illumina.com/sequencing/sequencing_software/igenome.ilmn)
and Ensembl. Plots were made using the R statistical software.51
2.3. Structural model and docking calculations of the
alternatively spliced S-catechol-O-
methyltransferase isoform
We modeled the (a)S-COMT isoform using discrete molecular
dynamics (DMD).10,45 InDMD,atomic interactions are approximated
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by square wells potential. Consequently, interactions can be
described as 2-body collisions, in which colliding atom’s velocity
changes instantaneously according to the conservation laws of
energy, momentum, and angular momentum. A united atom
representation is used to model protein structure, and the
solvation energy is accounted for using the Lazaridis–Karplus
implicit solvation model.26 We generated an initial model of (a)S-
COMT by mapping the protein amino acid sequence to the
crystallographic structure of S-COMT (V108 variant at 1.98 Å
resolution, PDB ID: 3BWM38). Because theN-terminal amino acid
sequence is identical between the 2 COMT isoforms, we
constrained the backbone coordinates of the first 154 residues
in (a)S-COMT and considered only their side chains flexibility.
Both backbone and side chains flexibility were allowed for the last
30 C-terminal amino acids, which are unique to (a)S-COMT
isoform. We performed an initial melting simulation to denature
the C-terminal portion of (a)S-COMT, and starting from this
preliminary structural model, we performed replica exchange36,58
DMD simulations to exhaustively sample the conformational free-
energy surface of the system. We completed a set of fifteen 106
time unit-long (;50 ns) replicas, in which temperature ranged
from 0.30 e/kB (;150 K) to 1.00 e/kB (;500 K) with an increment
of 0.05 e/kB (;25 K). Temperature was controlled with the
Andersen thermostat,2 and individual simulations were coupled
by means of Monte Carlo–based exchange at periodic interval
(;50 ps). The minimized lowest energy conformation of (a)S-
COMT was retrieved as the final (a)S-COMT structural model.
For all docking calculations, we used the 1.98 Å resolution
structure of the V108 variant of wild-type human S-COMT [PDB
ID: 3BWM38] and the lowest energy conformation of the (a)S-
COMT, as obtained from replica exchange DMD simulations. We
prepared protein structures using the protein preparation wizard
in Maestro (version 8.5; New York, NY). We retained the cofactor
S-adenosyl-methionine (SAM), the catalytic Mg21 ion, and
a conserved Mg21-coordinating water oxygen atom (OW), which
is crucial for substrate binding and catabolism. We removed the
cocrystallized ligand 3,5 dinitrocatechol, all crystallization ions,
and the remaining water molecules from the original protein
structure.We introduced SAM, theMg21 ion, andOW to the (a)S-
COMT isoform by superimposition to the S-COMT structure. We
then added hydrogen atoms to both protein structures. To avoid
steric clashes and relax in the 2 starting structures, we performed
energetic minimization using the default settings in the Maestro
protein preparation wizard. We built and obtained 3-dimensional
coordinates of 3,4-dihydroxibenzoic acid (DHBA), epinephrine,
norepinephrine (Supplementary Figure S6, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/
A120), and dopamine (Fig. 3B) molecules using the LigPrep
(version 2.8; New York, NY) program available in the Schrödinger
Suite. We used Glide (version 5.0; New York, NY) in standard
precision mode to perform all docking calculations. We centered
a 15-Å-sided cubic box on the catalytic Mg21 ion, encompassing
the binding site, and the van der Waals radii of all ligand atoms
with partial atomic charge less than 0.15 were scaled by a factor
0.8 to soften the potential for nonpolar ligand moieties. In
addition, we modeled the coordinate covalent bonds existing
between the catalytic Mg21 ion and ligand catechol hydroxyl
groups by introducing a restraint potential to bring ligand–ion
atompairs within the crystallographic distance (approximately 2.3
Å). The introduction of restraints to model the coordination
complex around the catalytic ion was crucial to improve the
quality of docking solutions. Without application of such feature,
neither Glide nor MedusaDock9,57 (our in-house developed
docking algorithm that simultaneously accounts for ligand and
receptor flexibility but does not implement restraint potentials), was
able to recapitulate the binding mode of the cocrystallized ligand
3,5-dinitrocatechol in the S-COMT-binding site. For each docked
ligand, we retained only the lowest energy poses featuring
crystallographic-like distances between the ligand catechol
hydroxyl groups and the catalytic Mg21 ion. We identified the
top-scoring conformer for each ligand on the basis of the Emodel13
score, whereas comparing different substrates accounting for their
corresponding Gscore13 values (Glide-recommended strategy).
The described procedure demonstrates high reliability, reproduc-
ing the binding pose of the cocrystallized 3,5-dinitrocatechol with
a ligand root-mean-square deviation of 0.43 Å.
Furthermore, we evaluated the binding affinity of SAM using
our in-house developed physics-based scoring function Medu-
saScore57 for the 2 COMT isoforms, S- and (a)S-COMT. We
retained the crystallographic coordinates of Mg21, OW, 3,5-
dinitrocatechol, and water molecules localized in SAM-binding
site of S-COMT. Also, we introduced Mg21, dinitrocatechol, and
waters’ atomic coordinates to (a)S-COMT structure by superim-
position to the wild-type isoform. We used Glide and the above-
described settings to dock SAM in a 15-Å-sided cubic box
centered on the SAM-binding sites of the 2 isoforms. We ranked
docking poses on the basis of the Emodel13 score and estimated
their binding energies with MedusaScore.57 The first ranked
poses recapitulated the crystallographic conformation of SAM in
S-COMT and its superimposed pose in (a)S-COMT with a ligand
root-mean-square deviation of 0.29 and 0.74 Å, respectively.
2.4. Construction of alternatively spliced catechol-O-
methyltransferase plasmids
Full-length pCMV-SPORT6-based cDNA clone corresponding to
the original (a)MB-COMT (ENST00000403184) and carrying
rs165774G allele was obtained from the IMAGE clone collection
(Open Biosystems, Huntsville, AL). The (a)S-COMT clone including
the transcriptional start site was constructed using the unique
restriction enzyme Bacillus species M (BSPMI). To make the (a)
COMT clones carrying rs165774A, we performed site-directed
mutagenesis using the QuickChange II XL Site-Directed Mutagen-
esis Kit (Stratagene, LaJolla, CA) according to the manufacturer’s
instruction, using forward and reverse primers containing the
1610G to A mutation (CTGCTGTTAGCAGCCAGACTAGGAG-
CACGAG and CTCGTGCTCCTAGTCTGGCTGCT AACAGCAG,
respectively; IDT, Coralville, USA). rs165774 is in perfect LD in
Caucasian population with another SNP in the 3 prime un-
translated region (39-UTR) of the alternatively transcribed COMT
isoform—rs165895—and original (a)COMT clones carried minor
allele for this SNP, rs165895C; thus, we have also performed
site-directed mutagenesis using forward and reverse primers
containing the 2108C to T mutation (GTAGAGATGGGGTTTCAC-
CACATTGGCCandGGCCAATGTGGTGAAACCCCATCTCTAC,
respectively; IDT) to create (a)MB- and (a)S-COMT-GT or (a)MB-
and (a)S-COMT-AC clones. Plasmid DNAs were purified using the
EndoFreePlasmidMaxi purification kit (Qiagen,Germantown,MD),
and sequences were confirmed by double sequencing at the
University of North Carolina at Chapel Hill core sequencing facility.
2.5. Transient transfection of catechol-O-methyltransferase
cDNA clones
MB-COMT, (a)MB-COMT-GT, (a)MB-COMT-AC, S-COMT, (a)S-
COMT-GT, or (a)S-COMT-AC were independently transiently
transfected into a human neuroblastoma cell line (Be2C) using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance
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with the manufacture’s recommendations. The amount of
plasmid was kept at 2.0 mg per well in a 6-well plate experimental
setting. Transfection with the vector lacking the insert was
performed for each experiment. Cell lysates were collected
approximately 48 hours after transfection. All experiments were
performed in triplicate.
2.6. Substrate concentration–velocity curves of catechol-O-
methyltransferase activity
Curves were generated for MB-COMT and S-COMT, and their
alternative counterparts carrying only major alleles, (a)MB-COMT-G
and (a)S-COMT-G. Approximately 48 hours after transfection,
medium was removed, cells were washed twice with 0.9% saline
solution (1 mL/35 mm well), covered with 200 mL of buffer (10 mM
Tris pH 7.4, 1 mM MgCl2, and 1 mM dithiothreitol), scraped,
collected in 1.7-mL tubes, freeze/thawed (280˚C/room tempera-
ture) twice, centrifuged at 13,000 g for 10 minutes, and then lysate
was collected in new tubes. Protein concentration of the samples
was determined based on the bicinchoninic acid method using
Pierce protein assay kit (Pierce Biotechnology, Rockford, IL).
Catechol-O-methyltransferase enzyme activity for concentration
curves was assessed as previously described.18 Briefly, 20 mg of
protein was incubated at 137˚C in 100 mM phosphate buffer (pH
7.4) containing 5 mM MgCl2, 200 mM SAM, and 5 to 8 increasing
concentrations of each substrate up to 3 mM: DHBA, dopamine,
norepinephrine, or epinephrine. A high-performance liquid chroma-
tography system with electrochemical detection was used to
analyze the reaction products, vanillic acid, 3-methoxytyramine,
normetanephrine, or metanephrine, respectively. The system
consisted of a sample autoinjector (Prominence SIL-20AC; Shi-
madzu, Kyoto, Japan), a pump (Jasco pu-2080, Tokyo, Japan), an
RP-18 column (3 mm, 4.6 3 100 mm; Waters Spherisorb, Milford,
MA), a coulometric detector (ESA Coulochem model 5100A
detector and a model 5011A cell; ESA Inc, Chelmsford, MA), and
Azur 5.0 software (Datalys, St. Martin D’Heres, France). The mobile
phase, which consisted of 0.1 MNa2HPO4 (pH 2.5-3.5), 0.15 to 0.4
mM EDTA, 5% to 25% methanol and 0 to 150 mg/L octane
sulphonic acid, and the detector potentials (E1 0-1200 mV and E2
1400-1500 mV) were selected according to COMT reaction
product; the flow rate was 1.0 mL/min. Data are expressed as
picomoles of each product (vanillic acid, 3-methoxytyramine, NMM,
or metanephrine) formed in 1 minute per milligram of protein in the
sample, corrected for mRNA amount. Substrate–velocity curves
were generated using nonlinear fitting for enzyme kinetics, using
GraphPad Prism (version 4.0; San Diego, CA) (Figs. 3C-F), and
complete results showing 95% confidence limits of enzymatic
capacity (Vmax, corrected formRNAexpression) and affinity (Km) are
shown in Supplementary Table S8 (available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A120). These experi-
ments were performed 3 times, and for fitting to the curve, outliers at
the highest substrate levels were excluded. Fitting r values for each
COMT isoform with each substrate tested were 0.94 or higher,
except for MB-COMT with dopamine (0.838).
2.7. mRNA relative expression analysis
RNA from cells independently transfected with MB-COMT, (a)
MB-COMT-G, (a)MB-COMT-A, S-COMT, (a)S-COMT-G, or (a)
S-COMT-A was extracted approximately 48 hours after trans-
fection and isolated using Trizol reagent (Invitrogen). The
isolated RNA was treated with Turbo DNase (Ambion/Life
Technologies, Carlsbad, CA) and reverse transcribed by
Superscript III reverse transcriptase (Invitrogen). The cDNA
was amplified with FastStart Universal SYBR Green Master mix
(Roche, Indianapolis, IN) using forward and reverse PCR
primers (TGAACGTGGGCGACAAGAAAGG CAAGAT and
TGACCTTGTCCTTCACGCCAGCGAAAT, respectively, for
COMT; and TGAAGGTCGGAGTCAACGGATTTGGT and
CATGTGGGCCATGAGGTCCACCAC for glyceraldehyde 3-
phosphate dehydrogenase, housekeeping gene used as
control for transcription efficiency). Applied Biosystems
7900HT Fast Real-Time PCR System (Applied Biosystems/Life
Technologies, Carlsbad, CA) was used for measuring fluores-
cence. Six independent experiments were conducted in
triplicates. Data were normalized to glyceraldehyde 3-
phosphate dehydrogenase and are presented as the average
6 standard error fold change to respective conventional
isoform (Figs. 4A, B).
2.8. Effect of rs165774 on catechol-O-
methyltransferase activity
To assess the putative effect of SNP rs165774 on enzymatic
performance, activity of S-COMT, MB-COMT, (a)S-COMT-G, (a)
S-COMT-A, (a)MB-COMT-G, and (a)MB-COMT-A was assessed
using 400 mM of DHBA as a substrate. The raw COMT activity
(picomoles of vanillic acid formed in 1 minute per milligram of
protein in the sample) and the activity normalized by mRNA level
are given. Three independent experiments were conducted in
triplicate, and data are presented as mean 6 standard error fold
change to respective conventional isoform (Figs. 4C-F).
2.9. Western blot
Purified lysates from an experiment used for enzymatic activity
with DHBA were run on 12% Mini-PROTEAN TGX precast gels
(Bio-Rad Laboratories Inc, Hercules, CA) and transferred to
polyvinylidene fluoride membrane (Bio-Rad) using the Transblot
Turbo (Bio-Rad). Blots were cut into 2 strips at 37 kDa marker
level, the first containing COMT and the second containing
b-actin. Blots were blocked with 5% nonfat milk for 1 hour at
room temperature and then incubated with COMT rabbit poly-
clonal 1˚ antibody (AB5873, 1:10,000;Millipore, Temecula, CA) or
b-actin rabbit polyclonal antibody (Ab8227; AbCam, Cambridge,
United Kingdom) overnight at 4˚C. After washing the membranes
with Tween-Tris-buffered saline, the blots were incubated with
goat anti-rabbit IgGHRP polyclonal 2˚ antibody (1:3000; Bio-Rad)
for 1 hour at room temperature. Blots were washed with Tween-
tris buffered saline and then exposed to chemiluminescence
reagent (Clarity Western; Bio-Rad) and developed on high-
sensitivity film (Figs. 4G, H).
3. Results
3.1. Association analysis in 2 human cohorts
Two independent human TMD cohorts were assessed in
case–control association analyses. In the discovery TMD case–
control cohort, we found that among all densely situated SNPs
tested within the COMT gene locus, only the P value for SNP
rs165774 was lower than threshold of significance in such way
that minor A allele is protective against risk of TMD (P 5 0.003,
OR 5 0.621, 0.452 , confidence interval [CI] , 0.852; Fig. 1A,
Supplementary Table S1, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A120). Because risk of
TMD has been previously associated with COMT haplotypes in
the central haploblock—low pain sensitivity, APS, and HPS8—in
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such way that the HPS haplotype is a risk factor for TMD,46 we
explored the relationship of SNP rs165774 with the haplotypes.
We found them to be in high LD (D9 5 0.985, r2 5 0.323), with
rs165774’s minor A allele situated almost exclusively in the APS
haplotype, with a frequency of 31.3% in this haplotype, but
contributing independently to TMD risk (Supplementary Figure
S1a and Supplementary Figure S2b, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/
A120). Contribution of SNP rs165774 demonstrated stronger
effect than that of the HPS haplotype, which was not significant
by itself in this cohort, likely due to the smaller sample size of the
TMD case–control cohort in comparison with the original analysis
demonstrating the effect of the HPS haplotype.46 We then
focused our study on the effects of this SNP.When examining the
association of this SNP with the sensitivity to pain-evoking stimuli
in the TMD case–control cohort, we found that the minor A allele
is also associated with lesser pressure pain sensitivity (P5 0.002,
b 5 21.712, 22.782 , CI , 20.641; Fig. 1B, Supplementary
Table S3, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A120).
In theOPPERA cohort, theminorA allele was again associated
with lesser pressure pain sensitivity, and within other QST tested
in the OPPERA but not in the TMD case–control cohort, with
a reduced duration of lingering pain after termination of noxious
heat stimuli, diminished sensitivity to mechanical stimuli, and
with a reduced duration of lingering pain after termination of
noxious mechanical stimuli (Supplementary Figure S1b and
Supplementary Table S4, available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A120). The com-
bined P value from a meta-analysis demonstrated a protective
effect of the minor A allele against both risk of TMD (P 5 0.014,
OR5 0.81, 0.685,CI, 0.958) andpressure pain sensitivity (P5
0.001, b 5 20.880, 21.399 , CI , 20.360) (Fig. 1A, B, and
Supplementary Table S5, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A120).
3.2. Gene structure and mRNA expression of the new
catechol-O-methyltransferase isoform
Investigation of the chromosomal location of SNP rs165774
indicated that it is situated in the 39-UTR of a potential alternatively
spliced COMT transcript, (a)-COMT, that shares its 59 sequence
with the reference MB-COMT mRNA. The evidence for expres-
sion of (a)-COMT transcript includes expressed sequence tags
(ESTs) in the European Nucleotide Archive (CR616943 and
BX449536.2, expression in the fetal brain). This transcript is
generated by intron retention 39 to exon 5 and contains alternative
polyadenylation site, producing a different transcript with 2217
nucleotides encoding 5 exons, 3 of which are coding (Fig. 1C).
This (a)-COMT mRNA codes for an alternative isoform of the
protein with a unique 30 amino acids terminus (Supplementary
Figure S2a, available online as Supplemental Digital Content at
Figure 1. Association analysis results and genomic localization of SNP rs165774 (G.A, minor allele frequency: 0.315). (A) Forest plot depicting odds ratios (OR;
with 95% confidence intervals) for COMT SNP rs165774 and risk of TMD; (B) Forest plot depicting regression coefficient (b; with 95% confidence intervals) for
COMT SNP rs165774 and pressure pain. The analysis was performed in TMD case–control andOPPERA cohorts; CI, 95% confidence interval; L95, lower bound
of 95% confidence interval; Meta, meta-analysis; OR, odds ratio; U95, upper bound of 95% confidence interval; b, regression coefficient. (C) Alternative (a)MB-
COMT transcript (CR616943 and BX449536.2) shares its 59 sequence with MB-COMT—one of the 2 reference COMT transcripts. At base pair (bp) position 865,
transcription leaks through intron 5 until polyadenylation site, creating an alternative splice variant. Red star: alternatively spliced COMT transcript; purple star:
reference MB-COMT isoform; green star: reference S-COMT isoform.
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http://links.lww.com/PAIN/A120). A similar transcript that shares
the same coding region has been identified in the human brain.54
We then conducted nucleotide and amino acid sequence
comparisons in mammals and found that the human (a)-COMT
transcript is highly conserved in primates (Supplementary Figure
S2b, available online as Supplemental Digital Content at http://
links.lww.com/PAIN/A120) with strong evidence of protein
selection (dN/dS 5 0.24 and 0.36 in the human–chimp and
human–gorilla comparisons, respectively). Specifically, highly
conserved alternative protein termini with strong conservation
of positions of stop codons are found in both chimp and gorilla
genomes (Supplementary Figure S2b, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/
A120). Multiple alignments of primates showed that SNP
rs165774 is located in a highly conserved sequence of the 39-
UTR and might potentially be involved in the regulation of
transcript stability and translation for being targeted by micro-
RNAs. Differential downstream effects could also be triggered as
COMT itself hosts micro-RNA mir4761. Searching for the
expression pattern of the (a)-COMT transcript, we performed
analysis of publically available deep sequencing data of mRNA
expression, which suggested that the (a)-COMT is expressed
across primates, from human to chimp to gorilla (Fig. 2A,
Supplementary Table S7, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A120). The estimation of
the relative expression of the (a)-COMT throughout various
tissues indicates that the new isoform is expressed in multiple
tissues including several brain regions, with the highest levels in
the cerebellum (Z score almost all positives) at approximately
10% of the reference isoform (Fig. 2B).
3.3. Structural model and docking calculations of the
alternatively spliced S-catechol-O-
methyltransferase isoform
Starting from the crystallographic structure of the wild type
S-COMT isoform (PDB: 3BWM),38 we have predicted the in silico
model of the (a)S-COMT isoform and compared its respective
structural features. The wild-type enzyme is characterized by
a Rossman fold with a methyltransferase domain, a catechol-
binding hairpin loop, and a so-called hydrophobic wall that
interacts with catecholamine’s ethylamine chains.38 The active
site of S-COMT, where methylation of substrates occurs,
includes both the enzymatic cofactor SAM-binding domain and
the catalytic pocket. The structural model of (a)S-COMT reveals
an enzyme with shorter C-terminus (Fig. 3A). The alternative
enzyme lacks 1 of the 2 terminal a-helices existent in S-COMT
and is capped by shorter terminal b-strands. The hairpin loop
between the 2 b-strands, which forms the catechol-binding
pocket, is significantly shorter in (a)S-COMT and no longer in
proximity of the catalytic site of the enzyme. The 6 residues of
the S-COMT hairpin loop involved in the catechol binding (ie,
P174, L198, E199, Y200, R201, and E202, Supplementary
Figure S3a, available online as Supplemental Digital Content at
Figure 2. Expression levels of COMT isoforms. The relative expression level (%) of the (a)MB-COMT vs the MB-COMT is compared between primates and tissue
types. (A) The expression levels are estimated from mRNA-Seq data (GEO set GSE30352), the region highlighted in grey is assessed. The raw mRNA-Seq data
pileup (clipped at height 25) are shown for cerebellum (CB) and testis (TS), in both male (M) and female (F) individuals from human (top), chimp (middle), and gorilla
(bottom). The exon tracks for the reference S-COMT, reference MB-COMT, and (a)MB-COMT isoform are shown. The last exon—unique for (a)MB-COMT
isoform—is colored in red; the last exon—unique for reference isoforms—is colored in yellow. (B) Z scores are computed from the distribution of expression levels
across tissues in a given species. Tissue types include cerebellum (CB, magenta), testis (TS, blue), brain minus cerebellum, heart, kidney, and liver (Oth, grey).
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http://links.lww.com/PAIN/A120) are missing in (a)S-COMT.
Therefore, only 2 residues from the hydrophobic wall (ie, W38
and M40) constitute the catechol-binding site in (a)S-COMT
(Supplementary Figure S3b, available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A120). All residues
that bind SAM are located within the first 155 residues of COMT
and, thus, are identical between the 2 COMT isoforms.52We then
performed docking calculations to estimate the binding proper-
ties of a minimal catechol model, DHBA, norepinephrine,
epinephrine (Supplementary Figure S4, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/
A120), and dopamine (Fig. 3B) in the active sites of S-COMT
and (a)S-COMT. The obtained estimated interaction energies
(Supplementary Table S7, available online as Supplemental
Figure 3. Predicted (a)S-COMT crystal structure and docking poses of dopamine and measured substrate concentration–COMT velocity curves. (A)
Crystallographic structure of S-COMT (red), computationally determined structural model of (a)S-COMT as extracted from DMD simulations (blue), and
superimposition of both. (B) Zoomed view of best dopamine docking solutions for S-COMT and (a)S-COMT (carbon atoms of ligands, SAM, and (a)S-COMT
residues are represented in green, grey, andwhite, respectively. Catalytic Mg21 ion andMg-coordinating conservedwater molecule are represented as a pink and
red sphere, respectively; see Supplementary Table S7 (available online as Supplemental Digital Content at http://links.lww.com/PAIN/A120) for chemical
structures of catecholamines and docking energy values). (C-F) Cell lysates from Be2C cells transfected with vectors expressing (C) MB-COMT or (D) S-COMT, or
their alternative counterparts (a)-COMT isoforms, (E) (a)MB-COMT or (F) (a)S-COMT were tested using DHBA, dopamine (DA), norepinephrine (NE), and
epinephrine (E). The fitted kinetic valueswith 95%confidence limits are given in Supplementary Table S7 (available online as Supplemental Digital Content at http://
links.lww.com/PAIN/A120).
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Digital Content at http://links.lww.com/PAIN/A120) combined
with the in silico structural model of the (a)S-COMT suggest an
enzyme isoform with a shallower catalytic pocket that retains part
of the active site and is less capable of stable interactions with
low-molecular-weight substrates compared with S-COMT.
3.4. Substrate concentration–velocity curves of catechol-O-
methyltransferase activity
We then tested the enzymatic activities of both (a)S- and (a)MB-
COMT isoforms on the above-mentioned substrates and
compared them with their correspondent reference isoforms.
First, our experimental results demonstrate that both (a)-COMT
isoforms are catalytically active, validating the functionality of the
newfound isoforms. In agreement with computational results, the
enzymatic activities of (a)-COMT isoforms were lower than those
of the reference (Figs. 3C-F and Supplementary Table S8,
available online as Supplemental Digital Content at http://links.
lww.com/PAIN/A120). As judged from Vmax values, this differ-
ence was particularly high in the case of soluble enzymes.
Second, we unexpectedly observed substantial differences in the
substrate–velocity pattern of (a)-COMT isoforms for different
catechol-containing substrates, such that the highest enzymatic
capacity was seen for dopamine, but no enzymatic activity was
observed for epinephrine. This substrate–velocity pattern was
very similar between (a)-COMT isoforms. Also, (a)MB-COMT,
such as MB-COMT, displayed generally lower Vmax values
towards all substrates than their respective (a)S-COMT and
S-COMT isoforms. The capacity (expressed as picomoles of
each product formed in 1 minute per milligram of protein in the
sample) of (a)MB-COMT was very similar to MB-COMT for DHBA
(7.7 and 8.1, respectively) and dopamine (8.7 and 6.5, re-
spectively) but lower for norepinephrine (5.1 and 12.6, re-
spectively). The capacity of (a)S-COMT was generally much
lower than the reference S-COMT (8.2 and 73.1 for DHBA, 11 and
55.3 for dopamine, and 14.8 and 78.3 for norepinephrine,
respectively). Affinity values (Km) were notmuch different between
the reference MB- and S-COMT isoforms but were increased in
(a)MB- and (a)S-COMT enzymes for DHBA (0.63 vs 0.12 and 0.38
vs 0.04, respectively). Also unexpectedly, the unique C-terminus
Figure 4. Relative mRNA expression, enzymatic activity, and protein expression levels of reference and alternative COMT isoforms and their allelic variants.
Fold change in relative mRNA expression level of (A) S-COMT and its alternative counterparts (a)S-COMT-G and (a)S-COMT-A, and of (B) MB-COMT and its
alternative counterparts (a)MB-COMT-G and (a)MB-COMT-A. Enzymatic activity with DHBA (normalized to mRNA amount) of (C) of S-COMT and its
alternative counterparts (a)S-COMT-G and (a)S-COMT-A, and of (D) MB-COMT and its alternative counterparts (a)MB-COMT-G and (a)MB-COMT-A.
Enzymatic activity with DHBA of (E) (a)S-COMT and (F) (a)MB-COMT isoforms only, as extracted from (C) and (D). Protein expression of (G) (a)S-COMT and (H)
(a)MB-COMT isoforms. Data are expressed as mean 6 SEM. *P , 0.05, **P , 0.01, ****P , 0.001, and ****P , 0.0001.
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of (a)MB- and (a)S-COMT enzymes did not substantially affect
their affinity compared with their reference isoforms towards
dopamine (0.19 vs 0.12; 0.25 vs 0.13, respectively) or norepi-
nephrine (0.52 vs 0.44; 0.63 vs 0.59, respectively).
3.5. Effect of rs165774 on mRNA stability, protein level, and
catechol-O-methyltransferase activity
Next, we assessed the effect of the minor A allele of rs165774 on
mRNA stability, protein expression, and enzymatic activity of both
(a)MB- and (a)S-COMT. On the one hand, we found that mRNA
stability of the variants carrying the major G allele [(a)MB- and
(a)S-COMT-G] was significantly decreased compared with their
respective alternative counterparts [(a)MB- and (a)S-COMT-A]
(Figs. 4A, B), which in turn, was not different from their respective
reference isoforms (MB- and S-COMT). On the other hand,
protein expression and enzymatic activity levels of the variants
carrying the major G allele were significantly higher than those
carrying the minor A allele, and all alternative variants displayed
lower enzymatic activity than their respective reference isoforms
(Figs. 4C-H). Combined, these findings show that although the
minor A allele increases mRNA stability, it also substantially
decreases its activity, most likely through modulation of trans-
lational efficiency. Thus, (a)-COMT variants carrying the rs165774
minorA allele encode for considerably less active enzymes, which
in turn could impact pain-related phenotypes.
4. Discussion
In this study, we tested 2 independent human cohorts
characterized for pain phenotypes and demonstrated the pain
protective effect associated with minor A allele of SNP rs165774.
This SNP is in high LD with the APS haplotype, the only COMT
haplotype that carries the well-studied met allele at SNP rs4680,
which yields an enzyme with decreased thermostability and
generally associated with higher sensitivity to pain.28 Thus, we
further investigated whether SNP rs165774 was simply marking
for the functional effect of the met allele. Interestingly, we found
the opposite to be true: the direction of association with the met
allele variant, marked in this study by the APS haplotype, was
contradictory to what was expected and driven by SNP
rs165774, such that only the APS haplotype carrying the minor
A allele of SNP rs165774 was protective against risk of TMD.
These findings stress the importance of considering SNP
rs165774 when constructing COMT haplotypes and represent
a new example of complex multilocus and heterogeneous effects
within the COMT gene locus.44 It has been proposed that
compensatory changes that follow functional mutations like met
allele are likely to be a ubiquitous force in the genome
evolution,21,23,24 but they are very challenging to identify.44 The
pain protective effect associated with the minor A allele of SNP
rs165774 was observed for pressure pain sensitivity in both
cohorts, and combined meta-analysis demonstrated a robust
protective effect of the minor A allele for both risk of TMD and
pressure pain sensitivity. This effect was also significant for
certain experimental pain modalities tested only in the
OPPERA cohort.
Besides the 2 reference MB- and S-COMT, multiple alternative
COMT isoforms have been reported, none of which have thus far
shown to be functional.54 Because SNP rs165774 is located in an
intronic region of the reference COMT isoforms, we investigated
its chromosomal location relative to other potential isoforms and
identified that it is situated in the 39-UTR of an alternatively spliced
MB-COMT isoform, for which sequence had been reported but
not characterized (ESTs CR616943 and BX449536). This
alternative COMT transcript is generated by the coordinated
regulation of alternative splicing and polyadenylation and codes
for an alternative terminus of the COMT protein. Recent studies of
mammalian gene expression revealed widespread alternative
initiation and alternative termination of transcription. They
highlight the important contributions of alternative termination of
transcription to the generation not only of transcriptome diversity
but also of protein end variability.41,43 It is recognized that
patterns of alternative splicing and polyadenylation are strongly
correlated with regulatory motifs conservation in both alternative
introns and in 39-UTR, which in turn indicates the joint
contribution of both splicing and polyadenylation in tissue-
specific regulation.32,41,56 Taking into account the results of
a previous genome analysis of alternative isoforms and their
variable protein ends,41 we compared the (a)-COMT nucleotide
and amino acid sequences in mammals. We found the transcript
to be highly conserved in primates, showing strong protein
selection especially in chimp and gorilla. Our results also show
that SNP rs165774 is in a highly conserved region of the (a)-
COMT mRNA 39-UTR that might be targeted by a number of
miRNAs, which might potentially contribute to regulation of its
stability and translation.
The analysis of deep sequencing data did not only further
support the evidence for (a)-COMT expression but also allowed to
estimate its relative expression, which ranged from 1% to 12% of
the level of the reference isoforms, where lower bounders were
defined by sensitivity of the analysis and by the coverage of
sequencing data. Notably, the tissue-specific pattern across
primates was conserved with the highest expression level of the
new isoform in the cerebellum. It is important to note that a similar
transcript has been reported to be expressed in the human
brain,53 although available nucleotide databases do not report
this transcript. The latter transcript is formed by similar
mechanism of intron retention 39 to exon 5 but does not contain
alternative polyadenylation site. Regardless of exact 39-UTR of
this transcript variant, it shares the same coding region with ESTs
CR616943 and BX449536.2 and thus should display identical
biological activity.
In an attempt to predict whether the enzyme encoded by the (a)
S-COMT transcript would be functional, we modeled the in silico
structure of the (a)S-COMT and observed that the alternative
enzyme retains a catalytic pocket, which is less capable of
stabilizing low-molecular-weight substrates though. We then
performed docking calculations to explore the binding properties
of catecholamine neurotransmitters (dopamine, epinephrine,
norepinephrine, and DHBA as a control molecule) in the active
site of (a)S-COMT and compared them with those of the
reference S-COMT. The change of coordination geometry
around the catalytic Mg21 along with enhanced solvent exposure
of the substrates caused decreased stability of binding of
catecholamines in (a)S-COMT, as evidenced by the lower
docking scores. We do not exclude the possibility that alternative
rearrangements of water molecules in the catalytic pocket may
establish alternative coordination geometries around the Mg21
ion. Furthermore, because the binding site of (a)S-COMT is
shallow and solvent exposed, the binding of alternativemolecules
would be possible but characterized by labile interactions.
Our experimental results demonstrate that both (a)S-COMT
and (a)MB-COMT isoforms are catalytically active, confirming the
functionality of the newly identified isoforms. Remarkably, (a)-
COMT isoforms displayed a unique substrate–velocity pattern,
such that no enzymatic activity was detected for epinephrine,
which was mainly associated with a COMT-related pain
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pathway.34 Instead, preferred enzymatic activity was found for
dopamine. Enzymatic activity toward dopamine was such that (a)
MB-COMT showed higher capacity and affinity, and (a)S-COMT
showed higher affinity than their respective reference isoforms.
Hence, our results indicate not only that (a)-COMT isoforms are
functional but also are likely to contribute to pain through
analgesic dopaminergic16 rather than adrenergic pathways.34
The (a)-COMT isoforms, thus, represent a rare example where
alternatively spliced isoforms display dramatically different sub-
strate specificity than reference isoforms. Although enzymatic
activity levels of (a)-COMT are lower compared with reference
COMT enzymes, our findings that they are catalytically active
combined with our association results provide strong evidence
that (a)-COMT enzymes are functionally important for pain
transmission.
Our experimental results also demonstrate that (a)-COMT
transcripts carrying the minor A allele of SNP rs165774 are as
stable as the reference COMT transcripts, whereas stability is
reduced in transcripts carrying the major G allele. Contrary to
what would be expected, the enzymatic activity and protein
expression levels of the allelic variants do not parallel the mRNA
stability findings. That is, although mRNA stability is higher for (a)-
COMT transcripts carrying the minor A allele of SNP rs165774,
enzymatic activity and protein expression levels are lower. This
provides a new example of allelic variants affectingmRNA stability
and protein expression in opposite directions. The molecular
genetic mechanisms underlying this effect often include regula-
tion of secondary and tertiary mRNA structures and have been
demonstrated for at least 2 other functional alleles of COMT,53
where more stable mRNA structures are protected from
degradation but also decrease the efficiency of translation33,53
and/or reflect the possibility of silencing mechanism involvement
in the regulation.15
Our results present a new pathway for COMT contribution to
human pain processing, as we have shown that (a)-COMT
enzymes display preferred activity towards dopamine. Catechol-
O-methyltransferase is expressed in multiple brain areas involved
in the processing of pain perception, such as the prefrontal cortex
and several other brain regions, the spinal cord, and peripheral
structures. As catecholamines are essential components of both
ascending and descending pain pathways, changes in COMT
activity can importantly modify such perception. If in the
periphery, low COMT activity produces elevated adrenergic tone
with nociceptive effects,22,34,40 evidences have shown that, in the
spinal cord and brain, low COMT activity producing high
dopaminergic tone seems to have antinociceptive effects.17,39,40
Additionally, COMT, particularly MB-COMT, is crucial for the
metabolism of dopamine in central nervous regions with low
dopamine transporter density, such as the prefrontal cortex,30
where COMTmay account for up to one-half of its metabolism.18
In this new scenario, lower (a)-COMT activity is consistent with
higher dopaminergic tone and consequent antinociceptive
effect.48 This is in line with our clinical findings, which have
shown that individuals carrying rs165774’s minor A allele are
more resistant to the risk of developing a musculoskeletal pain
condition and are less sensitive to painful stimuli. Our results are
also in line with a recent report that also found a similar
association between rs165774 and sensitivity to heat pain.19
In summary, the identification of a functional SNP with
a substantial minor allele frequency within the COMT gene has
broad implications for both basic cell molecular biology and
medical fields. First, our findings open up a conceptually new
approach for examining the structure and function of the COMT
gene. Here, we show how results of association studies can be
translated into discovery of a new structural variant of a well-
studied enzyme. Second, our results provide strong evidence
that this SNP has an important modifying effect on COMT
enzyme function. Third, the new alternatively spliced COMT
isoform exhibits unique substrate specificity with no affinity for
epinephrine, but relatively high and specific affinity for
dopamine. Remarkably, and as a consequence of this, its
contribution to pain phenotypes is opposite to the reference
isoform: lower activity of (a)-COMT is associated with reduced pain
perception and risk of developing a common chronic musculo-
skeletal pain condition, suggestively by increasing dopamine levels
without affecting the metabolism of epinephrine.
Conflict of interest statement
This work was funded by the Canadian Excellence Research
Chairs (CERC) Program (http://www.cerc.gc.ca/home-accueil-
eng.aspx), Grant CERC08 to L.D.; by the National Institute of
Dental and Craniofacial Research (http://www.nidcr.nih.gov/),
National Institutes of Health (NIH), Grant Nos. U01DE017018 to
L.D., W.M., G.D.S., R.B.F., J.D.G., R.O. and R01DE016558 to
L.D.; by Pfizer Research Funds (http://www.pfizer.com/
responsibility/grants_contributions/grants_and _ contributions)
to L.D.; by the Brazilian Federal Agency for the Support and
Evaluation of Graduate Education (www.capes.gov.br), Grant
No. CAPES/PDEE 0968-11-0 to C.B.M. and C.M.R.-B.; by the
Intramural Research Program of the NIH, National Institute of
Environmental Health Sciences; by the Academy of Finland and
Sigrid Juselius Foundation (http://www.aka.fi/en-GB/A/), Helsinki,
Finland, Grant 125-7898 to PTM; and by the National Institute
of Neurological Disorders and Stroke (Grant PO1-NS045685 to
S.K.S.). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of themanuscript.
The other authors have no conflicts of interest to declare.
There are also no known conflicts of interest associated with
this publication, and there has been no significant financial
support for this work that could have influenced its outcome.
Acknowledgements
The authors thank all participants from the TMD case–control and
OPPERA cohorts for their contribution. The authors acknowledge
Dr. Bruce Weir for his contribution for the genetic design of the
OPPERA cohort, and Ms. Liisa Lappalainen, MSc, for running the
high-performance liquid chromatography for the COMT activity
assays shown here. This research was supported in part by the
IntramuralResearchProgramof theNational LibraryofMedicine,NIH.
Appendix A. Supplemental Digital Content
Supplemental Digital Content associated with this article can be
found online at http://links.lww.com/PAIN/A120.
Article history:
Received 18 December 2014
Received in revised form 13 April 2015
Accepted 11 June 2015
Available online 23 July 2015
References
[1] Altschul SF,Madden TL, Schaffer AA, Zhang J, Zhang Z,MillerW, Lipman
DJ. Gapped BLAST and PSI-BLAST: a new generation of protein
database search programs. Nucleic Acids Res 1997;25:3389–402.
October 2015·Volume 156·Number 10 www.painjournalonline.com 2081
  Copyright  2015 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
[2] Andersen HC. Molecular dynamics simulations at constant pressure and/
or temperature. J Chem Phys 1980;72:2384–94.
[3] Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization
of LD and haplotype maps. Bioinformatics 2005;21:263–5.
[4] Belfer I, Segall SK, Lariviere WR, Smith SB, Dai F, Slade GD, Rashid NU,
Mogil JS, Campbell CM, Edwards RR, Liu Q, Bair E, Maixner W,
Diatchenko L. Pain modality- and sex-specific effects of COMT genetic
functional variants. PAIN® 2013;154:1368–76.
[5] Bhalang K, SigurdssonA, SladeGD,MaixnerW. Associations among four
modalities of experimental pain in women. J Pain 2005;6:604–11.
[6] Brawand D, Soumillon M, Necsulea A, Julien P, Csardi G, Harrigan P,
Weier M, Liechti A, Aximu-Petri A, Kircher M, Albert FW, Zeller U,
Khaitovich P, Grutzner F, Bergmann S, Nielsen R, Paabo S, Kaessmann
H. The evolution of gene expression levels in mammalian organs. Nature
2011;478:343–8.
[7] Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and
genetic signatures of common musculoskeletal pain conditions. Nat Rev
Rheumatol 2013;9:340–50.
[8] Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I,
Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS,
Maixner W. Genetic basis for individual variations in pain perception and
the development of a chronic pain condition. Hum Mol Genet 2005;14:
135–43.
[9] Ding F, Yin S, Dokholyan NV. Rapid flexible docking using a stochastic
rotamer library of ligands. J Chem Inf Model 2010;50:1623–32.
[10] Dokholyan NV, Buldyrev SV, Stanley HE, Shakhnovich EI. Discrete
molecular dynamics studies of the folding of a protein-like model. Fold
Des 1998;3:577–87.
[11] Dworkin SF, LeResche L. Research diagnostic criteria for
temporomandibular disorders: review, criteria, examinations and
specifications, critique. J Craniomandib Disord 1992;6:301–55.
[12] Edgar RC. MUSCLE: a multiple sequence alignment method with
reduced time and space complexity. BMC Bioinformatics 2004;5:113.
[13] Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT,
RepaskyMP, Knoll EH, Shelley M, Perry JK, ShawDE, Francis P, Shenkin
PS. Glide: a new approach for rapid, accurate docking and scoring. 1.
Method and assessment of docking accuracy. J Med Chem 2004;47:
1739–49.
[14] Greenspan JD, Slade GD, Bair E, Dubner R, Fillingim RB, Ohrbach R,
Knott C, Mulkey F, Rothwell R, Maixner W. Pain sensitivity risk factors for
chronic TMD: descriptive data and empirically identified domains from the
OPPERA case control study. J Pain 2011;12(11 suppl):T61–74.
[15] Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs
predominantly act to decrease target mRNA levels. Nature 2010;466:
835–40.
[16] Hagelberg N, Jaaskelainen SK, Martikainen IK, Mansikka H, Forssell H,
Scheinin H, Hietala J, Pertovaara A. Striatal dopamine D2 receptors in
modulation of pain in humans: a review. Eur J Pharmacol 2004;500:
187–92.
[17] Jacobsen LM, Eriksen GS, Pedersen LM, Gjerstad J. Catechol-O-
methyltransferase (COMT) inhibition reduces spinal nociceptive activity.
Neurosci Lett 2010;473:212–15.
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